SPI-2012, Spectrum's third biological drug, is a long-acting Granulocyte Colony-Stimulating Factor (GCSF) that utilizes Hanmi Pharmaceuticals proprietary platform technology, LAPSCOVERYTM.
Granulocyte colony-stimulating factor stimulates the production of white blood cells by the bone marrow. A recombinant form of GCSF is used in appropriate cancer patients to accelerate recovery from neutropenia after chemotherapy, allowing higher-intensity treatment regimens to be given at full-dose and on schedule. Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells, making patients prone to infections, hospitalizations, and interruption of additional chemotherapy treatments.
Route of Administration
Mode of Action
Animal data is suggestive of: